Navigation Links
Lilly Announces Completion of Avid Acquisition and FDA Priority Review for florbetapir
Date:12/20/2010

INDIANAPOLIS, Dec. 20, 2010 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today announced that it has completed the acquisition of Avid Radiopharmaceuticals, Inc., a privately held company developing novel molecular imaging compounds intended for the detection and monitoring of chronic human diseases. The transaction, first announced on November 8, 2010, has received the approval of Avid stockholders and clearance under the Hart-Scott-Rodino Antitrust Improvements Act. All other closing conditions have also been met.

Under the terms of the definitive merger agreement, Lilly acquired all outstanding shares of Avid for an upfront payment of $300 million, subject to adjustment based on existing cash on hand at closing. Avid stockholders will also be eligible for up to $500 million in additional payments contingent upon potential future regulatory and commercial milestones for florbetapir. The impact of the acquisition will be reflected in Lilly's fourth quarter 2010 financial statements, but is not expected to be material.

Lilly and Avid are also pleased to announce that the U.S. Food and Drug Administration (FDA) has assigned priority review designation to the marketing application for florbetapir, Avid's lead program in development. Florbetapir is a molecular imaging agent under investigation for detecting the presence of amyloid plaque in the brain. Beta-amyloid plaque is a defining pathology of Alzheimer's disease. The Peripheral and Central Nervous System Drugs Advisory Committee of the FDA will hold a meeting to discuss florbetapir's new drug application on January 20, 2011.

About florbetapir

Florbetapir F 18 (18F-AV-45), used with positron emission tomography (PET) technology is being assessed for the ability to detect beta-amyloid plaque deposits in living patients. Florbetapir was the first beta-amyloid imaging compound to enter
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Manchester College Receives $35 Million Grant From Lilly Endowment for School of Pharmacy
2. Lilly Statement Regarding President Obamas Meeting With U.S. Business Leaders
3. Lilly Suspends Phase III Trial in Metastatic Melanoma
4. Lilly Declares First-Quarter 2011 Dividend
5. U.S. District Court Rules from Bench in Lillys Favor, Confirms Validity of Alimta Patent
6. Lilly Surpasses United Way 2010 Campaign Goal
7. Breast Cancer Message Barred in Eli Lillys Hometown
8. Eli Lilly and Company to Open a Diabetes-Focused Research Center in China
9. Lilly USA, LLC Wins Award in 2010 National Health Information Awards Program
10. Lilly CEO: Are We Getting Our Moneys Worth from Medical Innovation?
11. MacroGenics and Lilly Announce Pivotal Clinical Trial of Teplizumab Did Not Meet Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... SEATTLE , BERKELEY, Kalifornien, und KOPENHAGEN, ... CMC Biologics, Inc. , ein Weltmarktführer der ... und anderen therapeutischen Proteinen, gab heute bekannt, ... Expansionsstrategie der Produktionskapazität den Ausbau der nordamerikanischen ... , mit der Ergänzung  einer Einweg-Anlage Bioreactor ...
(Date:6/30/2015)... June 30, 2015  EnteroMedics Inc. (NASDAQ: ETRM ... neuroblocking technology to treat obesity, metabolic diseases, and other ... public offering  of 40,229,886 units. Each unit consists of ... A warrant to purchase one share of common stock, ... one share of common stock, at a purchase price ...
(Date:6/30/2015)... 2015  Egalet Corporation (Nasdaq: EGLT ... company focused on developing, manufacturing and marketing ... from a Category 3 human abuse liability ... oral oxycodone product candidate in late-stage clinical ... enough to require daily, around-the-clock opioid treatment ...
Breaking Medicine Technology:CMC Biologics baut GMP-Produktionskapazität in den USA aus 2CMC Biologics baut GMP-Produktionskapazität in den USA aus 3EnteroMedics Inc. Announces Pricing of $35.0 Million Public Offering of Common Stock and Warrants 2EnteroMedics Inc. Announces Pricing of $35.0 Million Public Offering of Common Stock and Warrants 3Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 2Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 3Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 4Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 5
... YONKERS, N.Y., Sept. 27, 2011 As a result ... that could be dangerous to their health, according to ... Americans who currently take a prescription medicine told pollsters ... a doctor,s visit or medical procedure, declining tests, or ...
... Pa., Sept. 27, 2011 Inovio Pharmaceuticals, Inc. (NYSE ... development of synthetic immunogens against cancers and infectious diseases, ... Research and Development Agreement (CRADA) with the United States ... Plum Island Animal Disease Center. This collaboration will evaluate ...
Cached Medicine Technology:Consumer Reports Poll: 48 Percent of Americans on Meds Making Risky Health Care Tradeoffs 2Consumer Reports Poll: 48 Percent of Americans on Meds Making Risky Health Care Tradeoffs 3Consumer Reports Poll: 48 Percent of Americans on Meds Making Risky Health Care Tradeoffs 4Consumer Reports Poll: 48 Percent of Americans on Meds Making Risky Health Care Tradeoffs 5Inovio Pharmaceuticals Enters Collaboration With U.S. Dept. of Homeland Security to Assess Foot & Mouth Disease Synthetic Vaccines' Potential to Help Ensure Nation's Food Supply Safety 2Inovio Pharmaceuticals Enters Collaboration With U.S. Dept. of Homeland Security to Assess Foot & Mouth Disease Synthetic Vaccines' Potential to Help Ensure Nation's Food Supply Safety 3Inovio Pharmaceuticals Enters Collaboration With U.S. Dept. of Homeland Security to Assess Foot & Mouth Disease Synthetic Vaccines' Potential to Help Ensure Nation's Food Supply Safety 4
(Date:6/30/2015)... , ... June 30, 2015 , ... According to a ... a $3.1 million grant to study how sensory stimuli can be used to “decrease ... on improving care for children with autism, will compare patient experience in a “typical ...
(Date:6/30/2015)... , ... June 30, 2015 , ... ... eyeglasses online , finally its here, http://www.express-glasses.com is proud ... rates, for many location, ask about shipping with DHL Express when calling or ...
(Date:6/30/2015)... ... 30, 2015 , ... Rocky Mountain Oils, a leading non-MLM supplier of ... a new CEO, Mr. Darold Francis. The changes will help enhance the company’s focus ... customers have come to know and respect for over eight years. , “I am ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... manager of HRA Healthcare Research & Analytics , a consultative healthcare market ... Inc. (MJH) family of businesses. HRA offers quantitative and qualitative, custom and multi-client ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... ... Digest discussed the advantages that fat transfer procedures had over breast implants ... fat transfer techniques create breasts that “look and feel natural,” have increased sensation, ...
Breaking Medicine News(10 mins):Health News:New Study Aims to Determine if Sensory Stimuli can Ease Dental Anxiety in Children, Notes Medical Center Dental Care 2Health News:New Study Aims to Determine if Sensory Stimuli can Ease Dental Anxiety in Children, Notes Medical Center Dental Care 3Health News:Eyeglasses Online - Express Glasses Announcing New International Shipping Using DHL 2Health News:Rocky Mountain Oils Adds New CEO, Announces Relocation of Operations to Orem, Utah 2Health News:HRA Healthcare Research & Analytics Welcomes 'Creative Problem Solver' as New Executive Vice President 2Health News:HRA Healthcare Research & Analytics Welcomes 'Creative Problem Solver' as New Executive Vice President 3Health News:Recent Article Advocating for Breast Reconstruction with Fat Transfers Successfully Outlines the Advantages of Transfer Procedures, Notes Beverly Hills Physicians 2Health News:Recent Article Advocating for Breast Reconstruction with Fat Transfers Successfully Outlines the Advantages of Transfer Procedures, Notes Beverly Hills Physicians 3
... Institute (BBRI) and the University of Pennsylvania have found ... green tea component EGCG, can prevent and destroy ... are the primary culprits in fatal brain disorders such ... published in the current issue of Nature Chemical ...
... Vaccine protected volunteers from virus linked to cervical cancer , ... vaccine Cervarix protects women from infection for longer than six ... the two types of HPV (HPV-16 and HPV-18) most commonly ... 800 women, aged 15 to 25, with a normal cervical ...
... cut risk factors linked to diabetes, cardiovascular trouble, , ... for just a couple of months, can significantly lower ... cluster of heart disease risk factors -- years later, ... the journal Diabetes . , In women who ...
... ... the iPhone or iPod touch. Pop up menu’s and one touch exporting keeps track of and ... ... new iPhone application for surgery, can be used by surgeons, residents, surgical interns, medical students, and ...
... ... as increase the risk of obesity. Treadmill desks have been show effective in lowering ... ... 2009 -- Two sleep studies illustrating the negative effects of sleep deprivation on the ...
... ... people to sanitize their hands anytime, anywhere, is now available. , ... (PRWEB) December 3, 2009 -- It still blazes across ... of stories about the spread of H1N1 influenza A (swine flu) . Reports of ...
Cached Medicine News:Health News:Green tea chemical combined with another may hold promise for treatment of brain disorders 2Health News:Cervarix Proves Effective Against HPV for Over 6 Years 2Health News:Breast-Feeding Can Help Mom's Heart Decades Later 2Health News:Breast-Feeding Can Help Mom's Heart Decades Later 3Health News:Treadmill Desks Lower Health Risks Caused by Lack of Sleep 2Health News:Finally, Some Good News about Swine Flu 2
... Integra II SP MRI-Compatible Anesthesia System is perfect ... more than one type of anesthetic agent. ... and due to its wider stance, has a ... ventilator bellows assembly is utilized in both the ...
... Market leader in soft tissue repair in ... has developed the latest evolution in orthopedic ... ORTHOCORD Suture is as strong as any ... importantly, ORTHOCORD Suture handles like ETHIBOND®., ,ORTHOCORD ...
... PURPLE NITRILE* product family offers a comprehensive ... gloves were designed as an alternative for ... hypersensitivity to natural rubber latex proteins. The ... from latex and other synthetic gloves. Custom ...
... and the distinctive COLOR PURPLE* distinguish ... them for sterile clinical procedures when ... required. Theyre designed as an alternative ... Type 1 hypersensitivity to natural rubber ...
Medicine Products: